---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-027462"
form_type: "8-K"
ticker: "CALC"
cik: "0001534133"
company_name: "CalciMedica, Inc."
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T06:59:11.165998+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# CalciMedica discontinues Phase 2 KOURAGE trial, extends cash runway to Q4 2026

## Summary
- Phase 2 KOURAGE trial discontinued following IDMC recommendation.
- Cash runway guidance updated: existing cash, equivalents, and short-term investments expected to fund operations into Q4 2026.
- Previously disclosed guidance expected funding into second half of 2026.
- No specific financial amounts or trial data disclosed in filing.

## SEC filing metadata
- accession: 0001193125-26-027462
- form_type: 8-K
- ticker: CALC
- cik: 0001534133
- company_name: CalciMedica, Inc.
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534133/000119312526027462/0001193125-26-027462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534133/000119312526027462/d40225d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-027462
- JSON: https://secwatch.observer/filing/0001193125-26-027462.json
- Plain text: https://secwatch.observer/filing/0001193125-26-027462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.